Globus Medical (GMED) Stock Price, News & Analysis

Globus Medical, Inc. (NYSE: GMED) is a musculoskeletal-focused medical device company in the surgical and medical instrument manufacturing industry. The company develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. Its business is organized around musculoskeletal solutions and enabling technologies, serving surgeons who treat patients with musculoskeletal disorders and trauma.

According to company disclosures, Globus Medical’s musculoskeletal solutions include medical devices and instruments used mostly for spinal and orthopedic procedures, while its enabling technologies include computer systems developed to enhance surgical capabilities. The company describes itself as a global musculoskeletal company dedicated to solving unmet clinical needs and changing lives, with activity in areas such as spine, orthopedic trauma, joint reconstruction, biomaterials, and enabling technologies.

Business focus and product categories

Globus Medical states that the vast majority of its revenue is generated from musculoskeletal solutions products. These products and instruments are used primarily in spinal and orthopedic procedures and are sold to hospitals, physicians, and surgical centers. The company also reports that more than half of its revenue is earned in the United States, with additional sales generated internationally.

The firm highlights a broad musculoskeletal focus that spans:

• Spine – including implants and technologies used in spinal surgery and fusion procedures.
• Orthopedic trauma – including systems aimed at fracture management and trauma care.
• Joint reconstruction – addressing joint-related musculoskeletal conditions.
• Biomaterials – materials that support musculoskeletal healing and reconstruction.
• Enabling technologies – computer and technology platforms intended to enhance surgical planning, navigation, and execution.

Within its trauma portfolio, Globus Medical has announced systems such as the ANTHEM™ Elbow Fracture System, which it describes as a plating portfolio designed to address a wide spectrum of elbow fractures with anatomically contoured plates and polyaxial locking technology. The company also reports a Power Portfolio that includes systems such as DuraPro™ and Verzera™, which are described as oscillating and high-speed drill systems integrated with its navigation platforms to support bone removal and soft tissue protection in surgical procedures.

Enabling technologies and navigation

Globus Medical’s enabling technologies segment includes computer systems designed to enhance surgical capabilities. The company highlights navigation and robotics-related platforms such as ExcelsiusGPS™ and ExcelsiusHub™, which integrate with systems like DuraPro™ and Verzera™. These technologies are described as supporting accuracy, efficiency, and confidence across navigated and non-navigated workflows, and as part of the company’s effort to advance robotic-assisted and navigated surgery.

The company indicates that its enabling technologies business includes navigation capabilities and power systems that are intended to improve procedural workflows, provide real-time visualization, and help safeguard delicate tissue during bone removal and decompression procedures.

Corporate profile and history

Globus Medical reports that it is based in Audubon, Pennsylvania. According to company information, it was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Over time, it has described its evolution from an implant and instrument provider to a musculoskeletal technology and solutions provider.

The company’s Class A common stock trades on the New York Stock Exchange under the ticker GMED. It files periodic and current reports with the U.S. Securities and Exchange Commission, including Forms 10-K, 10-Q, and 8-K, which provide additional details on its operations, risk factors, and financial performance.

Strategic activities and acquisitions

Globus Medical’s public communications reference merger and acquisition activity as part of its growth strategy. The company has discussed the merger with NuVasive and the acquisition of Nevro Corp. and subsidiaries, and has referred to integration efforts and synergy capture related to these transactions. Management commentary in earnings releases has highlighted the contribution of acquired businesses to revenue and the company’s focus on integrating these operations while pursuing organic growth.

The company also notes that it uses non-GAAP financial measures, such as non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP adjusted EBITDA, and base business sales excluding contributions from recent acquisitions, as additional indicators of operating performance. These measures adjust for items including litigation provisions, amortization of intangibles, merger and acquisition-related costs, restructuring-related costs, certain foreign currency impacts, bargain purchase gains, and gains and losses on strategic investments.

Intellectual property and legal matters

Globus Medical emphasizes the importance of its intellectual property. In public statements, the company has reported outcomes of patent litigation, including a jury verdict in its favor in a case involving expandable spinal fusion implants. It has stated that it invests in research and development and that it will enforce its patent rights against unauthorized use of its technology. These disclosures underscore the role of patents and proprietary technology in the company’s musculoskeletal and enabling technology offerings.

Leadership and governance

According to an 8-K filing, the company’s Board of Directors approved the appointment of Keith W. Pfeil as President and Chief Executive Officer, effective July 18, 2025, following his prior roles as Chief Operating Officer and Chief Financial Officer. The same filing notes the appointment of Kyle Kline as Chief Financial Officer, also effective July 18, 2025. The company’s governance disclosures describe these leadership transitions, related compensation changes, and committee assignments at the Board level.

Capital allocation and share repurchases

Globus Medical has announced a share repurchase program authorized by its Board of Directors, allowing the company to repurchase up to a specified dollar amount of its outstanding common stock. Management has characterized this program as part of its capital allocation strategy and has indicated that repurchases may be executed through open market or privately negotiated transactions, subject to market conditions, legal requirements, and other factors.

Geographic reach and revenue mix

The company reports that more than half of its revenue is earned in the United States, with additional revenue generated internationally. It describes itself as a global musculoskeletal company, with net sales reported across U.S. and international markets. Earnings releases and SEC filings provide breakdowns of U.S. and international net sales growth and constant currency performance.

Use of non-GAAP measures

Globus Medical’s public filings and press releases provide detailed definitions of its non-GAAP measures. These include:

• Non-GAAP adjusted EBITDA – net income before interest income, net and other non-operating expenses, income taxes, depreciation and amortization, stock-based compensation, litigation provisions, merger and acquisition-related costs, restructuring-related costs, certain foreign currency impacts, bargain purchase gains, and gains and losses from strategic investments.
• Non-GAAP net income and non-GAAP diluted EPS – net income and earnings per share excluding specified items such as litigation provisions, amortization of intangibles, merger and acquisition-related costs, restructuring-related costs, certain foreign currency impacts, bargain purchase gains, certain tax adjustments, and related tax effects.
• Non-GAAP free cash flow – net cash provided by operating activities, adjusted for restricted cash and reduced by purchases of property and equipment.
• Constant currency net sales growth – net sales growth calculated by translating current period sales at prior period exchange rates.
• Base business sales – sales excluding contributions from recent acquisitions such as Nevro Corp. and its subsidiaries.

The company states that these measures are used by management for planning and performance evaluation and that they have limitations compared to U.S. GAAP metrics.

GMED stock and investor information

Investors interested in GMED stock can review the company’s earnings releases, 8-K filings reporting quarterly and annual results, and other SEC filings for detailed financial and operational information. Globus Medical also hosts investor conference calls and webcasts in connection with its quarterly results, and provides archives of these events on its investor relations platform.